Although MDGI expression has been linked to tumour‐suppressive properties in breast cancer (Nevo et al, 2010), in gastric carcinomas MDGI associated with poor patient survival (Hashimoto et al, 2004) and in melanomas, its expression was upregulated during disease progression (Sumantran et al, 2015). This evidence concerns the gene FABP3 and melanoma.